Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 1, 2007

View Archived Issues

Investigational prokinetic 5-HT4 agonist advancing through the pipeline

Support for activation of SIRT1 as a novel approach to type 2 diabetes

Cadence increases enrollment of phase III trial of Omigard for LCSI reduction

Quigley Pharma initiates clinical trial of QR-449 for metabolic syndrome

Positive results for Phytopharm's liquid formulation of Myogane

Elan announces second quarter 2007 results

Positive results for Biolex's phase IIa trial of Locteron for hepatitis C

Ranbaxy claims new drugs for respiratory disorders

New treatment options for dermatological disorders divulged in recent patent

Recent patent literature discloses new antiobesity drugs

EvaMist approved by the FDA

Symposium features Sirtex's SIR-Spheres for colorectal liver metastases

Anadys and Novartis discontinue development of ANA-975 for HCV

Abbott voluntarily withdraws E.U. marketing authorization for Trudexa

Targacept initiates phase I clinical trial of TC-5619

ReNeuron acquires business assets from AmCyte

Threshold begins phase I trial of TH-302 for solid tumors

Regulatory update on satraplatin

GSK and Targacept to codevelop novel NNRs targeting therapeutics

Toyama receives marketing approval for Geninax in Japan

Clinical evaluation to commence for a new agent for hyperlipidemia

Eisai to begin trial to determine MTD of E-7107 in cancer patients

Elixir presents data on ghrelin- and sirtuin-based programs for metabolic diseases

Fludarabine plus cyclophosphamide for the treatment of CLL

First small-molecule HIV-1 Tat-PP-1 inhibitors designed to inhibit HIV-1 transcription described

Comparison of different formulations of mycophenolic acid in IgA nephritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...